Study #2023-1060
A phase 1/2, open-label, multi-center, first-in-human study of the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of STX-001 delivered by intratumoral injection in patients with advanced solid tumors as a monotherapy or in combination with Pembrolizumab.
MD Anderson Study Status
Enrolling
Treatment Agent
STX-001, Keytruda®
Description
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.